ScholarLens Back to search
1991•Annual Review of MedicineRequires access

Prevention and Treatment of Pneumocystis Carinii Pneumonia

Walter T. Hughes

Open publisher page 49 citations

Abstract

Several drugs are now available for the treatment and prevention of Pneumocystis carinii pneumonia. These include trimethoprim-sulfamethoxazole and pentamidine isethionate as first-line drugs and dapsone-trimethoprim, trimetrexate, piritrexim, fansidar, difluoromethylornithine, and clindamycin plus primaquine as drugs in later stages of clinical development. A hydroxynaphthoquinone, called 566C80, offers promise in preclinical studies. The use of corticosteroids in the supportive management of P. carinii pneumonitis is undergoing clinical study.

About this research paper

What this paper is about

Several drugs are now available for the treatment and prevention of Pneumocystis carinii pneumonia. These include trimethoprim-sulfamethoxazole and pentamidine isethionate as first-line drugs and dapsone-trimethoprim, trimetrexate, piritrexim, fansidar, difluoromethylornithine, and clindamycin plus primaquine as drugs in later stages of clinical development. A hydroxynaphthoquinone, called 566C80, offers promise in preclinical studies. The use of corticosteroids in the supportive management of P. carinii pneumonitis is undergoing clinical study.

Why it matters

OpenAlex reports 49 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Several drugs are now available for the treatment and prevention of Pneumocystis carinii pneumonia. These include trimethoprim-sulfamethoxazole and pentamidine isethionate as first-line drugs and dapsone-trimethoprim, trimetrexate, piritrexim, fansidar, difluoromethylornithine, and clindamycin plus primaquine as drugs in later stages of clinical development. A hydroxynaphthoquinone, called 566C80, offers promise in preclinical studies. The use of corticosteroids in the supportive management of P. carinii pneumonitis is undergoing clinical study.

Key concepts: Pneumocystis carinii, Pneumonia, Medicine, Coronavirus disease 2019 (COVID-19), Coronavirus, Intensive care medicine, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 2019-20 coronavirus outbreak

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Prevention and Treatment of Pneumocystis Carinii Pneumonia — Research Paper | ScholarLens